Trumenba Vaccine: Dosing, Side Effects, and MenB Protection

Trumenba is a vaccine designed to protect against invasive meningococcal disease caused by serogroup B bacteria, a group responsible for a disproportionate share of meningitis cases in adolescents and young adults. Approved for use in people aged ten and older, it works by targeting a specific protein on the surface of the bacterium rather than a sugar coating, which is the approach used by older meningococcal vaccines covering other serogroups. The vaccine has an unusual place in routine immunization schedules because it is typically recommended on a shared clinical decision basis rather than universally mandated, and understanding why requires looking at the disease it prevents, how the vaccine was built, and what its real-world track record looks like.

Why Serogroup B Gets Its Own Vaccine

Meningococcal disease is caused by the bacterium Neisseria meningitidis, which comes in several serogroups labeled by the type of polysaccharide capsule surrounding the cell. Vaccines against serogroups A, C, W, and Y have been available for years and are widely given to adolescents. Serogroup B, however, has a capsule that closely resembles molecules found on human nerve tissue, making a polysaccharide-based vaccine approach impractical. That similarity forced researchers to find a different target entirely, which is how protein-based vaccines like Trumenba came about.

Serogroup B is not the most common cause of meningococcal disease across all age groups, but it dominates in certain populations. During 2014 through 2017, serogroup B accounted for about three-quarters of meningococcal cases among undergraduate students in the United States.¹ First-year undergraduates living in residence halls face the highest risk, with disease rates roughly twelve times higher than in non-college peers of the same age.² Separate analyses have confirmed that the average annual incidence of serogroup B disease among college students is more than five times that of same-age people not in college.³ The disease itself is rare in absolute numbers, but when it strikes it progresses rapidly and can be fatal within hours, which is what drives the push for vaccination even when case counts are low.

What the Vaccine Is Made Of

Trumenba targets a protein called factor H binding protein (fHbp), which sits on the outer surface of the meningococcal bacterium. This protein is a virulence factor: it helps the bacterium evade the human immune system by grabbing onto a human blood protein called factor H, essentially disguising itself. Blocking fHbp with antibodies strips away that camouflage and allows the immune system to kill the bacterium.

The fHbp gene exists in the vast majority of serogroup B strains, but the protein comes in many variants. Researchers have catalogued more than 700 distinct sequence variants, which fall into two broad subfamilies (sometimes described as three antigenic variants).⁴ Trumenba addresses this diversity by including one representative protein from each subfamily. The two components are recombinant lipoproteins produced in E. coli bacteria, designated as variants A05 and B01.⁵ An interesting design feature is that the lipid portion of these lipoproteins acts as a built-in adjuvant, meaning the vaccine stimulates a strong immune response without needing a separate additive like aluminum salts.

Expression levels of fHbp on the bacterial surface vary quite a bit between strains, by as much as fifteen-fold.⁶ That variation matters for predicting vaccine coverage, because a strain that barely produces fHbp on its surface is harder for vaccine-induced antibodies to target. Researchers use a lab assay called MEASURE to quantify how much fHbp sits on the surface of a given strain; strains above a certain threshold have a high probability of being killed by the antibodies the vaccine generates.⁷

Dosing Schedules

Trumenba can be given on either a two-dose or a three-dose schedule, and the choice depends on how urgently protection is needed. For healthy individuals at routine risk, the standard approach is two doses spaced six months apart.⁸ Clinical trials have shown that this two-dose schedule produces an immune response comparable to a three-dose series.⁹

The three-dose schedule, given at zero, one to two, and six months, is reserved for people at increased risk or in outbreak situations where faster protection matters.¹⁰ The first two doses, given just a month or two apart, begin building immunity quickly, while the six-month dose consolidates the response. Both schedules produce strong bactericidal antibody responses against a range of serogroup B test strains representative of those circulating in Europe and the United States.¹¹

What Side Effects to Expect

The most common reactions after Trumenba are local: pain, redness, and swelling at the injection site. Systemic reactions like fatigue, headache, muscle pain, and chills are also reported at higher rates than with a placebo or comparison vaccine. In the clinical development program, these local and systemic reactions were more frequent in vaccinated participants compared to controls, but the overwhelming majority were mild to moderate and resolved quickly on their own.¹²

Serious adverse events have been rare and, when they occurred, were not more common in the vaccine group than in controls. A large phase 3 trial found that serious adverse events were reported in about 1.6% of Trumenba recipients versus 2.5% of those receiving a hepatitis A vaccine or saline, and serious events considered related to either vaccine were uncommon.¹³ When the reactogenicity events (the expected injection-site pain and short-lived symptoms) were removed from the analysis, the overall adverse event rates between the vaccine and control groups were similar.¹⁴ In practical terms, you should expect a sore arm and possibly feeling run-down for a day or two, but the safety profile has been reassuring across more than fifteen thousand vaccinated individuals studied in trials.¹⁵

How Long Does Protection Last

This is one of the trickier aspects of the vaccine. Shortly after completing a primary vaccination series, a high percentage of recipients have protective antibody levels. Depending on the specific schedule and test strain, somewhere between roughly 74% and 100% of adolescents showed protective antibody titers one month after their last dose.¹⁶ Those numbers decline during the first year and then plateau, with about 18% to 61% still showing protective levels at four years, depending on the study group and the bacterial strain tested.¹⁷

That wide range reflects two realities. First, not every bacterial strain is equally well covered, so antibody persistence varies by which strain is being tested. Second, the presence of circulating antibodies is not the only line of defense; immune memory cells can mount a rapid response upon encountering the real bacterium, even if measurable antibody levels have dropped. Booster doses given at four years produced a strong recall response, suggesting the immune system retains memory of the antigen.¹⁸ Still, the degree to which waning antibodies translate into waning real-world protection is an ongoing area of study. If your highest-risk period is the first year or two of college, the timing of vaccination matters: getting vaccinated well before that window opens gives you peak antibody levels when you most need them.

Trumenba Compared to Bexsero

The other licensed serogroup B vaccine, Bexsero, takes a different design approach. While Trumenba contains two variants of a single protein (fHbp), Bexsero includes fHbp as one of four protein antigens alongside an outer membrane vesicle component. The two vaccines are not interchangeable; once you start a series with one, you should complete it with the same product.

A genomic analysis of all invasive meningococcal isolates in Sweden over a five-year period found that the overall estimated strain coverage was similar for the two vaccines across all serogroups combined, about 55% for Bexsero and 57% for Trumenba. But when looking at specific serogroups, the picture diverges sharply. For serogroup B specifically, Trumenba’s estimated coverage was 90% compared to 67% for Bexsero. Bexsero, however, showed much higher estimated coverage against serogroups W and C, while Trumenba had a stronger showing against serogroup Y.¹⁹

These numbers come from genomic predictions based on the presence and type of vaccine target genes in each isolate, not from direct clinical efficacy trials comparing the two head to head. They are informative for public health planning, but genomic predictions and real-world protection are not the same thing. The important takeaway is that the two vaccines have complementary strengths. Some researchers have noted that combining information from both vaccines could theoretically cover nearly all circulating strains, though no single-person regimen currently uses both products.

Getting Trumenba Alongside Other Vaccines

Adolescents and young adults are already juggling several recommended vaccines, and fitting in a two- or three-dose meningococcal B series raises a practical question: can Trumenba be given at the same visit as other shots? The answer is generally yes. Clinical studies have shown that giving Trumenba at the same time as the quadrivalent meningococcal conjugate vaccine (MenACWY) and the tetanus-diphtheria-pertussis booster (Tdap) did not blunt the immune response to any of the vaccines and did not cause a meaningful increase in side effects beyond what Trumenba alone produces.²⁰

Broader reviews of co-administration data across multiple meningococcal vaccine studies have reached the same conclusion: giving Trumenba alongside other routinely recommended vaccines for this age group does not raise overarching safety concerns and generally preserves the immune responses to all the vaccines involved.²¹ This is helpful for busy schedules, because it means you do not necessarily need a separate appointment for each vaccine.

What Happened During Campus Outbreaks

Trumenba’s development was partly driven by a string of serogroup B outbreaks on university campuses in the United States starting around 2013, before any serogroup B vaccine was fully licensed in the country. Between 2013 and 2018, ten university-based outbreaks occurred; in response, all ten schools launched mass vaccination campaigns, with three primarily using Trumenba and seven using Bexsero.²²

First-dose vaccination coverage during these campaigns varied widely, from as low as 14% to as high as 98%. In five of the ten outbreaks, additional cases appeared anywhere from six to 259 days after the vaccination campaign began.²³ That does not mean the vaccine failed in those cases. Outbreak trajectories are inherently unpredictable, and many additional cases occurred before recipients had completed the full series or before antibody levels had time to build. The lesson from these campaigns was that reaching high coverage quickly is critical, because protection from a single dose is incomplete and the bacteria do not wait for a vaccination schedule to finish.

A Key Limitation: No Clear Effect on Carriage

One of the biggest success stories of the older meningococcal conjugate vaccines against serogroups A, C, W, and Y has been their ability to reduce bacterial carriage in the throat. By cutting down the number of people silently carrying the bacteria, those vaccines create herd immunity that protects even unvaccinated individuals. Trumenba does not appear to share this property. A study conducted at a Rhode Island college during a serogroup B outbreak and mass Trumenba vaccination campaign found no reduction in meningococcal carriage over time or with additional doses. Carriage prevalence on campus remained stable, suggesting the vaccine does not rapidly prevent acquisition or reduce throat carriage of serogroup B bacteria.²⁴

This means Trumenba’s benefit is largely individual rather than communal. It protects the person who receives it from developing invasive disease, but it does not stop them from carrying the bacteria in their throat and potentially passing it to others. That distinction is part of why universal mandates for serogroup B vaccination have been harder to justify from a public health standpoint compared to the conjugate vaccines. It also means that achieving high coverage within a population, while still important during outbreaks, does not produce the same cascading protection that conjugate vaccines offer.

The Cost-Effectiveness Debate

Meningococcal B disease is devastating when it occurs, but it is genuinely rare. That rarity creates a challenging cost-effectiveness equation. A Canadian analysis found that routine adolescent vaccination against serogroup B was associated with costs per quality-adjusted life-year well above commonly accepted thresholds, ranging from roughly $490,000 to $976,000 depending on the strategy modeled.²⁵ The authors noted that serogroup B vaccination is unlikely to meet widely accepted cost-effectiveness benchmarks given how few cases occur, but also cautioned that standard economic models may not fully capture the broader benefits of preventing a disease with such high case fatality and long-term disability among survivors.

This is the central tension behind the “shared clinical decision-making” recommendation that governs serogroup B vaccination in the United States and some other countries. Advisory bodies acknowledge that the vaccine works and that the disease is severe, but the numbers make it hard to justify mandating it for every adolescent when resources could be spent elsewhere. The result is that the decision often falls to individual patients and families, ideally in conversation with a clinician, and tends to be influenced by factors like whether the person is heading to college, living in a dormitory, or traveling to a region with higher disease rates.

A Pentavalent Vaccine on the Horizon

One of the practical headaches with serogroup B vaccines has been fitting them into an already crowded adolescent immunization schedule alongside the separate quadrivalent MenACWY vaccine. A pentavalent vaccine combining both is in development. A phase 2 study tested a single formulation that merges Trumenba with a MenACWY conjugate vaccine into one injection. The results showed that this combined vaccine was safe, well tolerated, and produced immune responses that were noninferior to giving the two vaccines separately.²⁶

If this pentavalent vaccine eventually makes it through later-stage trials and regulatory approval, it could simplify the process considerably. Instead of needing two separate vaccine series targeting different serogroups, a single product would cover A, B, C, W, and Y in one regimen. That kind of simplification has historically boosted vaccine uptake, because fewer appointments and fewer injections translate directly into more people actually completing their series. It also could reshape the cost-effectiveness calculus, since the marginal cost of adding serogroup B coverage to an already-mandated visit is much smaller than building a standalone vaccination program around it.

How Strain Coverage Is Predicted

Because serogroup B strains are so genetically diverse, public health laboratories need ways to predict whether circulating strains in a given region are likely to be covered by Trumenba. Two approaches are used. The first is genomic typing: sequencing the fHbp gene from clinical isolates and matching it against known vaccine-targeted variants. The second is a functional assay called MEASURE, which uses a monoclonal antibody to measure how much fHbp protein a particular strain actually displays on its surface. A strain might carry the right gene but express so little protein that vaccine-induced antibodies cannot effectively target it. The MEASURE assay addresses this by quantifying surface expression; strains above a certain fluorescence threshold have been shown to have about a 91% chance of being killed by vaccine-induced antibodies.²⁷

This kind of surveillance work is ongoing in many countries and directly informs vaccine policy. A country where circulating serogroup B strains express low levels of fHbp might expect less benefit from Trumenba, while a country dominated by high-expressing strains could expect broader coverage. Strain characterization is part of the reason that vaccine recommendations differ between countries, and it underscores why serogroup B vaccination is not a one-size-fits-all proposition even within the framework of a single licensed product.